Assessment of the Response to Etoricoxib in Patients With Ankylosing Spondylitis (AS) and Inadequate Response to greater than or equal to 2 NSAIDs.

Trial Profile

Assessment of the Response to Etoricoxib in Patients With Ankylosing Spondylitis (AS) and Inadequate Response to greater than or equal to 2 NSAIDs.

Completed
Phase of Trial: Phase III

Latest Information Update: 19 Jun 2015

At a glance

  • Drugs Etoricoxib (Primary)
  • Indications Ankylosing spondylitis
  • Focus Therapeutic Use
  • Most Recent Events

    • 19 Dec 2013 Status changed from recruiting to completed.
    • 30 Oct 2013 Parent and extension study results presented at the 77th American College of Rheumatology and the 48th Annual Meeting of the Association of Rheumatology and Health Professionals.
    • 01 Jun 2011 Planned end date changed from 1 Sep 2011 to 1 Apr 2012 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top